close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

36.01 +0.16 (+0.45%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Harmony Biosciences Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY): a strong growth stock preparing for the next leg up?. ↗
Based on a technical and fundamental analysis of NASDAQ:HRMY we can say: HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
News headline image
Expert Outlook: Harmony Biosciences Hldgs Through The Eyes Of 11 Analysts ↗
 
Via Benzinga
News headline image
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), a growth stock which is not overvalued. ↗
Discover HARMONY BIOSCIENCES HOLDINGS, an undervalued growth gem. NASDAQ:HRMY is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an... 
Via Chartmill
News headline image
Demystifying Harmony Biosciences Hldgs: Insights From 11 Analyst Reviews ↗
 
Via Benzinga
News headline image
Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—it's a hidden gem with strong fundamentals and an attractive price tag. ↗
When you look at HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
News headline image
Earnings Scheduled For February 25, 2025 ↗
 
Via Benzinga
News headline image
Demystifying Harmony Biosciences: Insights From 5 Analyst Reviews ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts ↗
 
Via Benzinga
News headline image
NASDAQ:HRMY is not too expensive for the growth it is showing. ↗
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) is not too expensive for the growth it is showing. 
Via Chartmill
News headline image
Harmony Biosciences (HRMY) Q4 2024 Earnings Call Transcript ↗
HRMY earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder ↗
Harmony Biosciences' FDA setback for pitolisant in idiopathic hypersomnia doesn't impact its 2025 revenue outlook, with a Phase 3 trial planned for late 2025. 
Via Benzinga
News headline image
Harmony Biosciences Crashes On Surprise Rejection For Bread-And-Butter Drug ↗
The agency rejected the drug in the application filing stage, which is earlier than usual. 
Via Investor's Business Daily
News headline image
While growth is established for NASDAQ:HRMY, the stock's valuation remains reasonable. ↗
HARMONY BIOSCIENCES HOLDINGS could be undervalued. NASDAQ:HRMY is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced. 
Via Chartmill
News headline image
NASDAQ:HRMY, a growth stock which is not overvalued. ↗
HARMONY BIOSCIENCES HOLDINGS was identified as a growth stock that isn't overvalued. NASDAQ:HRMY is excelling in various growth indicators while maintaining a solid financial footing. 
Via Chartmill
News headline image
Friday's after hours session: top gainers and losers ↗
After the conclusion of the US market's regular session on Friday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Analyst Expectations For Harmony Biosciences's Future ↗
 
Via Benzinga
News headline image
Earnings Outlook For Harmony Biosciences ↗
 
Via Benzinga
News headline image
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review ↗
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
News headline image
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. ↗
Some companies saw their shares skyrocket on preliminary reports, but others took hits. 
Via Investor's Business Daily
News headline image
Investors should take note of NASDAQ:HRMY, a growth stock that remains attractively priced. ↗
Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
News headline image
Don't overlook NASDAQ:HRMY—it's a hidden gem with strong fundamentals and an attractive price tag. ↗
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), an undervalued stock with good fundamentals. 
Via Chartmill
News headline image
Breaking Down Harmony Biosciences: 6 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Unveiling 6 Analyst Insights On Harmony Biosciences ↗
 
Via Benzinga
News headline image
Analyst Expectations For Harmony Biosciences's Future ↗
 
Via Benzinga
News headline image
Why Harmony Biosciences (HRMY) Stock Is Down 18% Today ↗
Harmony Biosciences shares are trading lower by 17% Wednesday afternoon. The company announced a public offering of up to 8 million common stock shares from selling shareholders. 
Via Benzinga
News headline image
Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript ↗
HRMY earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Harmony Bio, The No. 1 Biotech Stock, Surged On Its 'High-Quality' Beat ↗
The company is focused on developing its pipeline of sleep and epilepsy drugs. 
Via Investor's Business Daily
News headline image
Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says ↗
UBS has initiated coverage on Harmony Biosciences with a Buy rating and a price target of $56. UBS highlights Harmony's potential for growth, projecting a 19% CAGR for Wakix sales through 2026. 
Via Benzinga
News headline image
Harmony Biosciences (HRMY) Q2 2024 Earnings Call Transcript ↗
HRMY earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Beats Revenue for Q2 2024 ↗
HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today